Premium
CHEMOIMMUNOTHERAPY FOR MELANOMA WITH DTIC, ACNU, VCR AND OK432
Author(s) -
Jimbow Kowichi,
Yanbe Hideko,
Nishio Chieko
Publication year - 1981
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1981.tb02544.x
Subject(s) - chemoimmunotherapy , immunoadjuvant , melanoma , medicine , dacarbazine , cancer research , chemotherapy , cytotoxicity , immunotherapy , immunology , oncology , immune system , in vitro , chemistry , biochemistry
Combination chemotherapy (DTIC and VCR plus a new derivative of nitrosourea, ACNU) with a new immunoadjuvant of OK432 were evaluated as treatment for disseminated malignant melanoma. Eight subjects with this chemoimmunotherapy showed a significant increase in survival rate (p=0.037 at 8 months), when compared with 11 subjects on other therapy. The regimens were minimally myelo‐suppressive and toxic to liver functions. Cellular immunity with specific mitogens of autologous and allogeneic melanoma cells (MLTC) and non‐specific mitogens of PHA, Con A and PWM was well preserved. Cell‐mediated cytotoxicity against autologous melanoma cells appeared to be stimulated in a way similar to that which occurs with BCG immunoadjuvant therapy.